Supplementation With Lactococcus lactis LMG 27352: Lack of Beneficial Effects on Cardiometabolic Risk in Obese...

Recent evidence suggests that gut microbial imbalance may contribute to the pathogenesis of obesity-related metabolic disorders, including cardiovascular diseases. Although the underlying mechanisms remain incompletely understood, numerous studies have investigated the modulation of gut microbiota through probiotic supplementation as a potential preventive or therapeutic approach. This randomized, prospective, triple-blind, placebo-controlled clinical trial aimed to evaluate the effects of Lactococcus lactis, a probiotic with anti-inflammatory properties, on cardiometabolic risk factors associated with obesity.

Fifty-two adults with elevated waist circumference and at least one additional metabolic alteration, such as elevated blood pressure, triglycerides, or glucose or reduced high-density lipoprotein cholesterol were recruited and randomly assigned to either a probiotic or placebo group (n = 26 each) for 90 days. During the study, 5 participants from the probiotic group withdrew, resulting in 21 participants for the probiotic group's endpoint analyses. Neither group received guidance regarding food intake. Participants underwent assessments of anthropometry, body composition, dietary intake, and a range of biochemical markers.

No significant improvements were observed on cardiometabolic risk parameters following L lactis LMG 27352 supplementation. Dietary analysis further revealed a significant rise in carbohydrate intake in both groups.

The findings of this study suggest limited clinical efficacy of L lactis LMG 27352 supplementation in metabolic disorders related to obesity under the conditions investigated. These results underscore the critical influence of dietary patterns, particularly sodium and carbohydrate intake, which may have modulated or counteracted any potential benefits of the probiotic strain.